BiVictriX Therapeutics Plc (LON:BVX – Get Free Report) shares shot up 17.6% during mid-day trading on Wednesday . The stock traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). 1,538,020 shares changed hands during trading, an increase of 1,320% from the average session volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).
BiVictriX Therapeutics Stock Performance
The company has a debt-to-equity ratio of 8.81, a current ratio of 4.40 and a quick ratio of 7.49. The business’s fifty day simple moving average is GBX 9.66 and its 200 day simple moving average is GBX 10.88. The stock has a market cap of £8.25 million, a price-to-earnings ratio of -250.00 and a beta of -0.73.
Insider Buying and Selling at BiVictriX Therapeutics
In related news, insider Robert Edward Hawkins bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average price of GBX 7 ($0.09) per share, for a total transaction of £1,400 ($1,764.34). 42.56% of the stock is currently owned by company insiders.
About BiVictriX Therapeutics
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
See Also
- Five stocks we like better than BiVictriX Therapeutics
- How to Capture the Benefits of Dividend Increases
- Top-Performing Non-Leveraged ETFs This Year
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- 5 discounted opportunities for dividend growth investors
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for BiVictriX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiVictriX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
